Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Long-Term Deferred Tax (2019 - 2025)

Vanda Pharmaceuticals' Long-Term Deferred Tax history spans 9 years, with the latest figure at $103.1 million for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax rose 29.88% to $103.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $103.1 million, a 29.88% increase, with the full-year FY2024 number at $81.4 million, up 8.59% from a year prior.
  • Long-Term Deferred Tax hit $103.1 million in Q3 2025 for Vanda Pharmaceuticals, up from $97.1 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for VNDA hit a ceiling of $103.1 million in Q3 2025 and a floor of $67.8 million in Q3 2023.
  • Historically, Long-Term Deferred Tax has averaged $78.4 million across 5 years, with a median of $75.3 million in 2024.
  • Biggest five-year swings in Long-Term Deferred Tax: fell 11.89% in 2022 and later rose 29.88% in 2025.
  • Tracing VNDA's Long-Term Deferred Tax over 5 years: stood at $74.9 million in 2021, then fell by 1.12% to $74.0 million in 2022, then rose by 1.3% to $75.0 million in 2023, then rose by 8.59% to $81.4 million in 2024, then increased by 26.56% to $103.1 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for VNDA at $103.1 million in Q3 2025, $97.1 million in Q2 2025, and $89.1 million in Q1 2025.